What happened
Myungmoon Pharm reported consolidated results for FY2025: revenue of US$134M (+4.7% year on year), operating profit of US$4.7M (+254.4% year on year) and net income of US$1.09M (from a loss a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$134M |
|---|---|
| Revenue vs a year earlier | +4.7% |
| Operating profit | US$4.7M |
| Net income | US$1.09M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-11, Change of less than 30% in revenue or profit/loss structure (voluntary) |
| Source | DART rcept 20260211800714 → open original filing |
Source: DART. Information only, not investment advice.